ABOUT THIS EPISODE
Dr. Paul Peter Tak, President and CEO of Candel Therapeutics, sits down with Jonathan to discuss the company's sprint from positive Phase III results to commercial launch. They explore how Candel is redefining the biotech playbook — using an externalized, dynamic model to build commercial capabilities with speed and agility, without the burden of premature fixed costs.
Topics include Candel's viral immunotherapy CAN-2409 for localized prostate cancer, the overnight financing triggered by Phase III success, the "one team" approach to culture and external partners, and how a lean 80-person organization is delivering the output of a mid-sized pharma company.
- 0:00 — Introduction: Dr. Paul Peter Tak and Candel Therapeutics
- 1:19 — What CAN-2409 does differently for prostate cancer patients
- 3:19 — Integrating a viral immunotherapy into existing radiation workflows
- 4:48 — The day after Phase III: shifting from R&D to launch readiness
- 6:10 — Overnight financing and pressing the button with Merck Millipore
- 9:16 — Starting with the patient journey, not "medical affairs vs. commercial"
- 12:10 — Speed without fixed costs: the advantage of externalization
- 15:51 — The "one team" approach: culture over credentials
- 21:14 — The Halloween party: building trust through fun
- 23:21 — Six years without missing a single catalyst
- 26:06 — What success looks like after approval
- 29:07 — Leading remotely from Portugal: the hybrid model
- 33:24 — 80 people, mid-sized pharma output: freedom and accountability
- 34:41 — AI with RI: real intelligence
Pharma Sessions is hosted by Jonathan Kaskey
Follow along on LinkedIn: https://www.linkedin.com/in/jonkaskey/
Or join the Pharma Sessions Substack:
www.pharmasessions.substack.com
TRANSCRIPT 🔗
00:00:00.000 --> 00:00:01.300
I'm joined today by Dr.
00:00:01.300 --> 00:00:05.820
Paul Peter Tock president and CEO of Condell Therapeutics.
00:00:06.000 --> 00:00:18.670
For those of you that don't know, Condell is a clinical stage company, but not going to be clinical stage for much longer, and that's actually a lot of what we're going to talk about today.
00:00:18.920 --> 00:00:37.210
So they just-- and correct me w- if I misspoke, but you just delivered positive phase III results, a…